23. Li N, Chen Y, Zhang YM, Yang Y, Su Y, Chen JT, Liu Y (2014) Polysaccharide-gold
nanocluster supramolecular conjugates as a versatile platform for the targeted delivery of
anticancer drugs. Sci Rep 4:4164
24. Yang Y, Zhang YM, Chen Y, Chen JT, Liu Y (2016) Polysaccharide-based noncovalent
assembly for targeted delivery of taxol. Sci Rep 6:19212
25. Yang Y, Jia X, Zhang YM, Li N, Liu Y (2018) Supramolecular nanoparticles based on β-CD
modified hyaluronic acid for DNA encapsulation and controlled release. Chem Commun
54:8713–8716
26. Liu JH, Wu JX, Zhang YM, Liu Y (2018) Photocleavable supramolecular polysaccharide
nanoparticles for targeted drug release in cancer cells. Asian J Org Chem 7:2444–2447
27. Wang QF, Li SM, Wang ZY, Liu HZ, Li CJ (2009) Preparation and characterization of a
positive thermoresponsive hydrogel for drug loading and release. J Appl Polym Sci
111:1417–1425
28. Namgung R, Lee YM, Kim J, Jang Y, Lee BH, Kim IS, Sokkar P, Rhee YM, Hoffman AS, Kim
WJ (2014) Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat
Commun 5:3702
29. Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted,
nucleic acid-containing nanoparticles. Bioconjug Chem 18:456–468
30. Davis ME (2009) Design and development of IT-101, a cyclodextrin-containing polymer
conjugate of camptothecin. Adv Drug Del Rev 61:1189–1192
31. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668
32. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific
targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 104:15549–15554
33. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CHJ, Alabi CA, Mack BC, Davis ME
(2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging
and tumor histological measurements. Proc Natl Acad Sci U S A 106:11394–11399
34. Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME (2016)
CRLX101 nanoparticles localize in human tumors and not adjacent nonneoplastic tissue after
intravenous dosing. Proc Natl Acad Sci U S A 113:3850–3854
35. Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing
from live-cell and live-animal bioluminescent imaging. Nucl Acids Res 34:322–333
36. Bartlett DW, Davis ME (2008) Impact of tumor-specific targeting and dosing schedule on
tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Biotechnol Bioeng 99:975–985
37. Chao J, Lin J, Frankel P, Clark AJ, Wiley DT, Garmey E, Fakih M, Lim D, Chung V, Luevanos
E, Eliasof S, Davis ME, Yen Y (2017) Pilot trial of CRLX101 in patients with advanced,
chemotherapy-refractory gastroesophageal cancer. J Gastrointest Oncol 8:962–969
38. Hu Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific
knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a
murine model of metastatic Ewing’s sarcoma. Cancer Res 65:8984–8992
39. Schluep T, Hwang SJ, Cheng J, Heidel JD, Bartlett DW, Davis ME (2006) Preclinical efficacy
of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res
12:1606–1614
40. Heidel D, Yu Z, Liu JYC, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007)
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase sub-unit M2 siRNA. Proc Natl Acad Sci U S A
104:5715–5721
41. Numbenjapon T, Wang J, Colcher D, Schluep T, Davis ME, Duringer J, Kretzner L, Yen YS,
Forman J, Raubitschek A (2009) Preclinical efficacy of camptothecin-polymer conjugate IT101 in multiple human lymphoma xenograft models. Clin Cancer Res 15:4365–4373
19 Construction and Applications of Cyclodextrin Polymers in Biology
555
nanocluster supramolecular conjugates as a versatile platform for the targeted delivery of
anticancer drugs. Sci Rep 4:4164
24. Yang Y, Zhang YM, Chen Y, Chen JT, Liu Y (2016) Polysaccharide-based noncovalent
assembly for targeted delivery of taxol. Sci Rep 6:19212
25. Yang Y, Jia X, Zhang YM, Li N, Liu Y (2018) Supramolecular nanoparticles based on β-CD
modified hyaluronic acid for DNA encapsulation and controlled release. Chem Commun
54:8713–8716
26. Liu JH, Wu JX, Zhang YM, Liu Y (2018) Photocleavable supramolecular polysaccharide
nanoparticles for targeted drug release in cancer cells. Asian J Org Chem 7:2444–2447
27. Wang QF, Li SM, Wang ZY, Liu HZ, Li CJ (2009) Preparation and characterization of a
positive thermoresponsive hydrogel for drug loading and release. J Appl Polym Sci
111:1417–1425
28. Namgung R, Lee YM, Kim J, Jang Y, Lee BH, Kim IS, Sokkar P, Rhee YM, Hoffman AS, Kim
WJ (2014) Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat
Commun 5:3702
29. Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted,
nucleic acid-containing nanoparticles. Bioconjug Chem 18:456–468
30. Davis ME (2009) Design and development of IT-101, a cyclodextrin-containing polymer
conjugate of camptothecin. Adv Drug Del Rev 61:1189–1192
31. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668
32. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific
targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 104:15549–15554
33. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CHJ, Alabi CA, Mack BC, Davis ME
(2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging
and tumor histological measurements. Proc Natl Acad Sci U S A 106:11394–11399
34. Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME (2016)
CRLX101 nanoparticles localize in human tumors and not adjacent nonneoplastic tissue after
intravenous dosing. Proc Natl Acad Sci U S A 113:3850–3854
35. Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing
from live-cell and live-animal bioluminescent imaging. Nucl Acids Res 34:322–333
36. Bartlett DW, Davis ME (2008) Impact of tumor-specific targeting and dosing schedule on
tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Biotechnol Bioeng 99:975–985
37. Chao J, Lin J, Frankel P, Clark AJ, Wiley DT, Garmey E, Fakih M, Lim D, Chung V, Luevanos
E, Eliasof S, Davis ME, Yen Y (2017) Pilot trial of CRLX101 in patients with advanced,
chemotherapy-refractory gastroesophageal cancer. J Gastrointest Oncol 8:962–969
38. Hu Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific
knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a
murine model of metastatic Ewing’s sarcoma. Cancer Res 65:8984–8992
39. Schluep T, Hwang SJ, Cheng J, Heidel JD, Bartlett DW, Davis ME (2006) Preclinical efficacy
of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res
12:1606–1614
40. Heidel D, Yu Z, Liu JYC, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007)
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase sub-unit M2 siRNA. Proc Natl Acad Sci U S A
104:5715–5721
41. Numbenjapon T, Wang J, Colcher D, Schluep T, Davis ME, Duringer J, Kretzner L, Yen YS,
Forman J, Raubitschek A (2009) Preclinical efficacy of camptothecin-polymer conjugate IT101 in multiple human lymphoma xenograft models. Clin Cancer Res 15:4365–4373
19 Construction and Applications of Cyclodextrin Polymers in Biology
555